New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Eli Lilly and Company

LLY

Healthcare Drug Manufacturers General

Eli Lilly and Company’s revenue for fiscal 2025 (year ended December 2025) was $65.2 billion, up 44.7% from fiscal 2024.

Revenue
+38.6%
EPS
+16.3%
Free cash flow
+21.8%
Total debt
+15.0%

Quarter to September 2026, against a year earlier

1,351.35 0.30 −0.02%
Market cap
$1.27T
P/E
43.9×
Fwd P/E FY26e
42.2×
Dividend yield
0.51%
F-score
7/9
ROIC
26.4%
Net debt / EBITDA
1.2×
Payout ratio
0.2×

Eli Lilly and Company 10-Q filed Oct 30, 2025

Fiscal Q3 2025 · Period ended Sep 30, 2025 · Filed · accepted 11:15 AM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Aug 7, 2025: 2 added · 1 removed · 21 modified; 11 with only figures updated; 3 moved without change

  1. Modified · Financial Results

    Revenue increased for the three and sixnine months ended JuneSeptember 30, 2025, driven by increased volume, partially offset by lower realized prices. The increased volume and lower realized prices during the three and sixnine months ended JuneSeptember 30, 2025 were primarily driven by ZepboundMounjaro and MounjaroZepbound.